All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
This gene is a member of the aggrecan/versican proteoglycan family. The encoded protein is an integral part of the extracellular matrix in cartilagenous tissue and it withstands compression in cartilage. Mutations in this gene may be involved in skeletal dysplasia and spinal degeneration. Multiple alternatively spliced transcript variants that encode different protein isoforms have been observed in this gene.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L007 | Human anti-ACAN (ATEGRVRVNSAYQDK) T Cell Receptor, pMSGV1 | Human | Human | ATEGRVRVNSAYQDK | HLA–DR4+/DQ8 | retroviral vector | ||
TCR-L007Z | Human anti-ACAN (aa89-103) T cell receptor, pCDTCR1 | Human | Human | ATEGRVRVNSAYQDK | HLA–DR4+/DQ8 | Lentiviral | ||
TCR-YC0059 | Mouse anti-ACAN T cell receptor ((5/4E8)-1), pCDTCR1 | Human | 5/4E8 | Mouse | ATEGRVRVNSAYQDK | H2-IAd | Lentiviral vector | |
TCR-YC0060 | Mouse anti-ACAN T cell receptor ((5/4E8)-2), pCDTCR1 | Human | 5/4E8 | Mouse | ATEGRVRVNSAYQDK + CITR(R5) | H2-IAd | Lentiviral vector | |
TCR-YC0061 | Mouse anti-ACAN T cell receptor ((5/4E8)-3), pCDTCR1 | Human | 5/4E8 | Mouse | ATEGRVRVNSAYQDK + CITR(R5, R7) | H2-IAd | Lentiviral vector | |
TCR-YC0062 | Mouse anti-ACAN T cell receptor ((5/4E8)-4), pCDTCR1 | Human | 5/4E8 | Mouse | ATEGRVRVNSAYQDK + CITR(R7) | H2-IAd | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION